Leadership & Pay ·
Kenneth T. Mills resigns from board effective Oct 21; George Migausky appointed Chairman
RGNXREGENXBIO Inc.
REGENXBIO Inc. announced that director Kenneth T. Mills resigned from the Board, effective October 21, 2026, to focus on his new role as CEO of another company. The departure was not due to any disagreement regarding operations or policies. Concurrently, the Board appointed George Migausky as Chairman. Daniel Tassé stepped down as Lead Independent Director in accordance with governance guidelines but remains a Board member. REGENXBIO Inc. operates in the biotechnology industry, focusing on gene therapy and viral vector development.